Brands
Tata Motors taps Martin Uhlarik as new global design head
NEW DELHI: Indian automaker Tata Motors has tapped Martin Uhlarik as its new global design head. The announcement comes in the wake of his predecessor Pratap Bose’s decision to step down.
At present, it is unclear where Bose, who has been with the company for 14 long years, is headed to. He was instrumental in transforming the design language for all of Tata Motors Vehicles, some of which have gone on to win design awards over their lifetimes.
Previously, Uhlarik was working as the head of design for Tata Motors European Technical Centre (TMETC). A 27-year career veteran, he had joined Tata Motors back in 2016 as the head of design in the UK. He is also credited with the development of the Impact 3 generation of vehicles.
Uhlarik will continue to operate from TMETC in the UK, where he will lead teams in the three Tata Motors design centres in Coventry (UK), Turin (Italy) and Pune (India). He will report into Tata Motors president – passenger vehicle business unit Shailesh Chandra.
Tata Motors CEO & managing director Guenter Butschek said, “I am delighted to announce the appointment of Martin Uhlarik as the new global design head of Tata Motors. Martin is an experienced automobile designer with deep domain knowledge of design, keen understanding of international trends and extensive operational experience with leading automobile companies in several geographies. His rich experience and expertise will inspire our teams to further enhance our vehicle design philosophy and language. I take this opportunity to also thank Pratap for his services and wish him the best for the future.”
Uhlarik has a degree in industrial design from the Ontario College of Art and Design University in Toronto, Canada and a degree in Transportation Design from Art Center College of Design in Vevey, Switzerland.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
